Psoriasis was less likely to progress to psoriatic arthritis (PsA) among patients treated with interleukin-17 (IL-17) or ...

Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasisTop-line data from the 12-week double-blind ...

Scalp psoriasis improvement was maintained with long-term tildrakizumab treatment in what researchers said is the first ...

A real-world study in Spain finds faster improvements with induction therapy but highlights long-term drug survival ...

Not a lot of people know about psoriasis which is why several myths and misconceptions about the condition continue to ...

More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...

Super Bowl LIX champion Dallas Goedert of the Philadelphia Eagles shares his journey with plaque psoriasis. After 20 years of ...

Bristol Myers Squibb (BMS) has shared positive five-year results from a long-term extension (LTE) study of its oral TYK2 ...

A consistent safety profile and sustained efficacy were observed in patients with moderate to severe plaque psoriasis.

The following is a summary of “Vitamin B6 catabolism and psoriasis risk: A cross-sectional study,” published in the February ...

Bristol Myers Squibb announces positive data from POETYK PSO LTE trial of Sotyktu to treat moderate-to-severe plaque psoriasis: Princeton, New Jersey Tuesday, February 18, 2025, 1 ...

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.In the second of a three-part ...